Elanco Animal Health Incorporated $ELAN Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC decreased its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 65.1% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 33,298 shares of the company’s stock after selling 62,227 shares during the quarter. SG Americas Securities LLC’s holdings in Elanco Animal Health were worth $797,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. NewEdge Advisors LLC lifted its holdings in shares of Elanco Animal Health by 133.7% in the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after purchasing an additional 627 shares during the last quarter. Root Financial Partners LLC grew its stake in Elanco Animal Health by 50.7% during the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after buying an additional 592 shares during the last quarter. Uniplan Investment Counsel Inc. purchased a new position in Elanco Animal Health during the 4th quarter worth approximately $41,000. Torren Management LLC acquired a new position in Elanco Animal Health during the fourth quarter worth approximately $46,000. Finally, Farther Finance Advisors LLC increased its position in Elanco Animal Health by 43.6% during the fourth quarter. Farther Finance Advisors LLC now owns 3,089 shares of the company’s stock worth $70,000 after buying an additional 938 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

Insider Buying and Selling at Elanco Animal Health

In related news, insider Rajeev A. Modi purchased 4,911 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The stock was purchased at an average cost of $20.35 per share, with a total value of $99,938.85. Following the completion of the acquisition, the insider directly owned 160,812 shares in the company, valued at $3,272,524.20. This trade represents a 3.15% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Jeffrey N. Simmons acquired 4,971 shares of the stock in a transaction that occurred on Friday, May 15th. The stock was purchased at an average price of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the transaction, the chief executive officer owned 171,971 shares in the company, valued at $3,454,897.39. The trade was a 2.98% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 1.14% of the stock is owned by company insiders.

Elanco Animal Health Stock Down 0.2%

ELAN opened at $24.94 on Monday. The business has a 50 day moving average price of $23.20 and a two-hundred day moving average price of $23.69. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60. The company has a market cap of $12.46 billion, a PE ratio of -49.88, a P/E/G ratio of 1.63 and a beta of 1.68. Elanco Animal Health Incorporated has a 52 week low of $13.39 and a 52 week high of $27.72.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.06. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The company had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.28 billion. During the same period last year, the business posted $0.37 EPS. The company’s revenue was up 14.9% on a year-over-year basis. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. As a group, research analysts anticipate that Elanco Animal Health Incorporated will post 1.11 EPS for the current year.

Wall Street Analysts Forecast Growth

ELAN has been the subject of several research analyst reports. TD Cowen increased their price objective on Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, June 18th. Wall Street Zen cut shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 24th. UBS Group reiterated a “buy” rating on shares of Elanco Animal Health in a research report on Tuesday, March 10th. Citigroup increased their price target on shares of Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $28.55.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.